In this "science-to-strategy" installment of ACS-WRAP®,
Dr Harold L. Dauerman reviews the evolution of STEMI
and acute coronary syndromes (ACS) therapy, and discusses
the integration of bivalirudin into modern cardiovascular
(CV) practice for patients with STEMI and high-risk ACS.
In this edition of STEMI-WRAP, Dr. Gregg Stone, a leader
in the field of interventional cardiology trials, begins
by discussing the adverse consequences of bleeding in
general and the potential advantages of the direct thrombin
inhibitor bivalirudin. He then describes the results
of past trials of bivalirudin in ACS and PCI, namely
REPLACE-2 and ACUITY, and then gives a detailed analysis
of the results of HORIZONS-AMI, a trial of bivalirudin
monotherapy versus heparin plus GP IIb/IIIa therapy in
patients with STEMI undergoing PCI.
In this evidence-based, practice-focused edition of
STEMI-WRAP, Dr Charles V. Pollack discusses
the epidemiology and pathophysiology of STEMI, ACC/AHA
guidelines for STEMI treatment, general principles for
ED STEMI management, new trials focused on antiplatelet
therapy, and recommendations for antiplatelet and antithrombin
therapy in patients with STEMI.
In this important, practical, and timely edition of AntiplateletWRAP, Dr Sunil Rao, an expert in the field of interventional cardiology and bleeding, discusses issues related to antiplatelet therapy with the thienopyridine, clopidogrel, focusing on the relationship between clopidogrel use and bleeding complications in the setting of CABG surgery.
